Abstract:The application of chimeric antigen receptor (CAR) T cells in the management of hematological malignancies has emerged as a noteworthy therapeutic breakthrough. Nevertheless, the utilization and effectiveness of CAR-T cell therapy in solid tumors are still limited primarily because of the absence of tumor-specific target antigen, the existence of immunosuppressive tumor microenvironment, restricted T cell invasion and proliferation, and the occurrence of severe toxicity. This review explored the history of CAR-T and its latest advancements in the management of solid tumors. According to recent studies, optimizing the design of CAR-T cells, implementing logic-gated CAR-T cells and refining the delivery methods of therapeutic agents can all enhance the efficacy of CAR-T cell therapy. Furthermore, combination therapy shows promise as a way to improve the effectiveness of CAR-T cell therapy. At present, numerous clinical trials involving CAR-T cells for solid tumors are actively in progress. In conclusion, CAR-T cell therapy has both potential and challenges when it comes to treating solid tumors. As CAR-T cell therapy continues to evolve, further innovations will be devised to surmount the challenges associated with this treatment modality, ultimately leading to enhanced therapeutic response for patients suffered solid tumors.

What problem does this paper attempt to address?

The paper primarily explores the application, challenges, and improvement strategies of Chimeric Antigen Receptor (CAR) T-cell therapy in the treatment of solid tumors. It highlights the main issues currently faced by CAR-T cell therapy in treating solid tumors and proposes a series of methods to address these challenges. Specifically: 1. **Target Antigen Selection**: An ideal Tumor-Specific Antigen (TSA) should have high coverage, stability, and specificity. However, in solid tumors, there is a lack of suitable TSAs, and most current CAR-T cell therapies target Tumor-Associated Antigens (TAA), which may lead to off-target effects. 2. **Antigen Heterogeneity**: There is high heterogeneity within tumors, making traditional CAR-T cells capable of recognizing only a single tumor surface marker, allowing tumor cells to escape immune attack by altering antigen expression. 3. **Immunosuppressive Microenvironment**: The immunosuppressive network within the Tumor Microenvironment (TME), including Tumor-Associated Macrophages (TAM), regulatory T cells (Treg), and Myeloid-Derived Suppressor Cells (MDSC), inhibits the function of effector cells and accelerates T-cell exhaustion. To address the above issues, the paper proposes several strategies: - **Multi-CAR-T Cell Combination Therapy**: Enhancing the recognition ability of tumor cells by using multiple types of CAR-T cells. - **Bispecific CAR-T Cells**: Expressing two different CARs on a single cell to enhance anti-tumor effects. - **Synthetic Notch Logic-Gated T Cells**: Regulating gene expression through synthetic Notch receptors to achieve precise dual antigen recognition. - **Universal CAR**: Fifth-generation CAR design, increasing flexibility and broad-spectrum antigen recognition capability. - **Switchable CAR**: Introducing small molecules to regulate CAR-T cell activity, reducing toxicity and improving safety. - **Suicide Genes**: Using inducible caspase 9 and other suicide genes to reduce off-target toxicity. - **TME Modification**: Such as using CAR-T cells to target and reprogram TAMs, and combining with Immune Checkpoint Inhibitors (ICIs) to improve the TME. In summary, this paper aims to provide researchers and clinicians with effective information on how to overcome the obstacles of CAR-T cell therapy in the treatment of solid tumors.

Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

Current Progress in CAR-T Cell Therapy for Solid Tumors

Advanced Strategies of CAR-T Cell Therapy in Solid Tumors and Hematological Malignancies

Fine-Tuning through Generations: Advances in Structure and Production of CAR-T Therapy

Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment

Current progress in CAR-T cell therapy for tumor treatment

Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies

Adoptive cell therapy for solid tumors beyond CAR-T: Current challenges and emerging therapeutic advances

Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: challenges and opportunities.

Advances and Hurdles in CAR T Cell Immune Therapy for Solid Tumors

Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies

The dilemmas and possible solutions for CAR-T cell therapy application in solid tumors

Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments

Challenges and interventions of chimeric antigen receptor-T cell therapy in solid tumors

Emerging Approaches for Solid Tumor Treatment Using CAR-T Cell Therapy

Chimeric Antigen Receptor-T Cell Therapy for Solid Tumors Require New Clinical Regimens

Current Clinical Application of the CAR-T Cell Therapy

Bright future or blind alley? CAR-T cell therapy for solid tumors

A long way to the battlefront: CAR T cell therapy against solid cancers.

Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities